Evernorth announces another step forward in lowering drug prices by making a Stelara biosimilar available at $0 out of pocket for patients early next year
Evernorth Health Services has announced plans to offer a Stelara biosimilar at $0 out-of-pocket cost for eligible Accredo patients starting in early 2025. This initiative is expected to save patients an average of $4,000 annually. The biosimilar, produced by Quallent Pharmaceuticals, will be priced over 80% lower than Stelara's list price, offering significant savings for health plan sponsors.
Accredo, Evernorth's specialty pharmacy, currently serves over 30,000 Stelara patients and provides specialized support through its Therapeutic Resource Centers. This move follows Evernorth's successful introduction of a Humira biosimilar in June, which has already seen a 25% adoption rate among eligible patients.
Evernorth Health Services ha annunciato piani per offrire un biosimilare di Stelara a un costo di $0 per il paziente per i pazienti Accredo idonei a partire dall'inizio del 2025. Questa iniziativa dovrebbe far risparmiare ai pazienti una media di $4,000 all'anno. Il biosimilare, prodotto da Quallent Pharmaceuticals, sarà venduto a un prezzo superiore al 80% inferiore rispetto al prezzo di listino di Stelara, offrendo risparmi significativi per gli sponsor dei piani sanitari.
Accredo, la farmacia specialistica di Evernorth, attualmente serve oltre 30.000 pazienti in trattamento con Stelara e fornisce supporto specialistico attraverso i suoi Centri di Risorse Terapeutiche. Questa mossa segue l'introduzione di successo di un biosimilare di Humira da parte di Evernorth a giugno, che ha già registrato un tasso di adozione del 25% tra i pazienti idonei.
Evernorth Health Services ha anunciado planes para ofrecer un biosimilar de Stelara a un costo de $0 para el paciente para los pacientes elegibles de Accredo a partir de principios de 2025. Se espera que esta iniciativa ahorre a los pacientes un promedio de $4,000 al año. El biosimilar, producido por Quallent Pharmaceuticals, se cotizará a un precio más del 80% inferior al precio de lista de Stelara, ofreciendo ahorros significativos para los patrocinadores de los planes de salud.
Accredo, la farmacia especializada de Evernorth, actualmente atiende a más de 30,000 pacientes de Stelara y proporciona apoyo especializado a través de sus Centros de Recursos Terapéuticos. Este movimiento sigue la introducción exitosa de un biosimilar de Humira por parte de Evernorth en junio, que ya ha visto una tasa de adopción del 25% entre los pacientes elegibles.
Evernorth Health Services는 2025년 초부터 자격이 있는 Accredo 환자에게 스텔라라 바이오시밀러를 환자 본인 부담 $0으로 제공할 계획을 발표했습니다. 이 이니셔티브는 환자들에게 연평균 $4,000를 절약할 것으로 예상됩니다. Quallent Pharmaceuticals에서 생산하는 이 바이오시밀러는 스텔라라의 목록 가격보다 80% 이상 낮은 가격에 책정되어 건강 보험 후원자에게 상당한 절약을 제공합니다.
Evernorth의 전문 약국인 Accredo는 현재 30,000명 이상의 스텔라라 환자에게 서비스를 제공하며, 치료 자원 센터를 통해 전문 지원을 제공합니다. 이 조치는 Evernorth가 6월에 성공적으로 도입한 휴미라 바이오시밀러에 이어지는 것으로, 이미 자격이 있는 환자들 사이에서 25%의 채택률을 보이고 있습니다.
Evernorth Health Services a annoncé des plans pour proposer un biosimilaire de Stelara à un coût de 0 $ pour le patient pour les patients Accredo éligibles, à partir du début de 2025. Cette initiative devrait faire économiser aux patients en moyenne 4 000 $ par an. Le biosimilaire, produit par Quallent Pharmaceuticals, sera proposé à un prix plus de 80 % inférieur au prix de liste de Stelara, offrant des économies significatives pour les sponsors de plans de santé.
Accredo, la pharmacie spécialisée d'Evernorth, sert actuellement plus de 30 000 patients sous Stelara et fournit un soutien spécialisé par le biais de ses Centres de Ressources Thérapeutiques. Ce mouvement fait suite à l'introduction réussie d'un biosimilaire de Humira en juin, qui a déjà enregistré un taux d'adoption de 25 % parmi les patients éligibles.
Evernorth Health Services hat Pläne angekündigt, ein Biosimilar von Stelara für berechtigte Accredo-Patienten ab Anfang 2025 zu einem Eigenkostenbeitrag von $0 anzubieten. Es wird erwartet, dass diese Initiative den Patienten im Durchschnitt $4.000 jährlich einsparen wird. Das Biosimilar, das von Quallent Pharmaceuticals hergestellt wird, wird über 80% günstiger als der Listenpreis von Stelara sein und bietet erhebliche Einsparungen für die Sponsoren von Gesundheitsplänen.
Accredo, die Spezialapotheke von Evernorth, bedient derzeit über 30.000 Stelara-Patienten und bietet spezialisierte Unterstützung über ihre Therapeutischen Ressourcen-Zentren an. Dieser Schritt folgt der erfolgreichen Einführung eines Humira-Biosimilars im Juni, das bereits eine 25%ige Akzeptanzquote bei berechtigten Patienten erreicht hat.
- Offering Stelara biosimilar at $0 out-of-pocket cost for eligible patients
- Expected patient savings of $4,000 annually on average
- Biosimilar priced over 80% lower than Stelara's list price
- Potential for significant savings for health plan sponsors
- 25% adoption rate of Humira biosimilar among eligible Accredo patients
- None.
Insights
This announcement by Evernorth is a significant move in the pharmaceutical industry. By offering a Stelara biosimilar at
For investors, this move signals Evernorth's aggressive strategy to capture market share in the lucrative biosimilar space. The company's ability to leverage its supply chain and clinical expertise could lead to increased revenue and market dominance. However, investors should also consider the potential impact on profit margins, as the drastically reduced pricing might affect short-term financial performance.
Evernorth's initiative aligns with the broader healthcare policy goal of reducing drug costs. This move could potentially set a new industry standard, pressuring other companies to follow suit. The
From a policy perspective, this development might influence future healthcare legislation. Policymakers could view this as a model for encouraging competition and affordability in the pharmaceutical sector. However, it's important to monitor how this impacts innovation incentives in the original drug development pipeline.
The market implications of Evernorth's move are significant. With over 30,000 Accredo patients currently using Stelara, the potential for rapid adoption of the biosimilar is high. The success of the Humira biosimilar, with a
This trend could accelerate the growth of the biosimilar market, potentially reshaping the competitive landscape in the pharmaceutical industry. Investors should watch for similar moves by competitors and potential impacts on the original drug manufacturers' market share and revenue streams. The long-term effect could be a significant shift in pharmaceutical pricing models and market dynamics.
- Estimated to save individual Accredo patients around
$4,000 - Biosimilar price will be more than
80% lower than Stelara list price - Accredo patients benefit from the specialty pharmacy's best-in-class clinical support
"We continue to believe in the power of biosimilars to achieve significant savings for patients and plan sponsors now and into the future. We're already seeing strong interest in the Humira biosimilar made available to Accredo patients in June, and now we're focused on improving affordability and access to another widely used, high-cost treatment for a variety of inflammatory conditions," said Matt Perlberg, president of Evernorth Health Services' pharmacy and care delivery businesses. "We are uniquely positioned to lower costs because of the leading capabilities we have in navigating the supply chain as well as the clinical expertise to help achieve the best patient health outcomes."
The biosimilar price will be more than
More than 30,000 Accredo patients currently use Stelara, supported by specialty-trained pharmacists and nurses in Accredo's Therapeutic Resource Center for inflammatory conditions. Accredo's 15 condition-specific Therapeutic Resource Centers connect patients with pharmacists and nurses 24 hours a day, 7 days a week, helping to ensure patients receive care from clinicians who specialize in their condition and who take the time to understand their circumstances.
In June, Evernorth made an interchangeable Humira biosimilar available, and more than
About Evernorth Health Services
Evernorth Health Services creates pharmacy, care and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE: CI), or third-party partners. Learn more at evernorth.com.
Media Contact:
Justine Sessions
Justine.Sessions@evernorth.com
860-810-6523
View original content to download multimedia:https://www.prnewswire.com/news-releases/evernorth-announces-another-step-forward-in-lowering-drug-prices-by-making-a-stelara-biosimilar-available-at-0-out-of-pocket-for-patients-early-next-year-302238655.html
SOURCE Evernorth Health Services
FAQ
When will Evernorth make the Stelara biosimilar available for $0 out-of-pocket?
How much can patients save annually with the Stelara biosimilar offered by Evernorth?
What is the price difference between the Stelara biosimilar and the original Stelara?
How many Accredo patients currently use Stelara?
What percentage of eligible Accredo patients are using the Humira biosimilar introduced in June?
